Physician profile
Travis Hardin
NPI 1831503259
$1,513.21
in general payments reported to CMS, 2019-2025
12 companies · $689 in 2025
The $689 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $52.54 · 2022: $144 · 2023: $317 · 2024: $311 · 2025: $689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,252 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,252.16 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $701.31 | 2021-2025 | |
| Corcept Therapeutics | $318.48 | 2024-2025 | Korlym |
| Novo Nordisk INC | $117.72 | 2025 | Rybelsus, Ozempic |
| Exact Sciences Corporation | $70.69 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $67.56 | 2023 | Trelegy Ellipta, Arexvy |
| Otsuka America Pharmaceutical, INC. | $64.08 | 2025 | Rexulti |
| Pfizer INC. | $48.91 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.40 | 2025 | Xifaxan |
| Astrazeneca Pharmaceuticals Lp | $32.17 | 2023-2024 | Airsupra, Breztri |
| Idorsia Pharmaceuticals US INC | $22.91 | 2025 | Quviviq |
| Amgen INC. | $17.95 | 2025 | Evenity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.03 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Hardin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.